Abstract

The overall objective of the clinical core is to provide the necessary resources to support the clinical components of the projects. This support will be divided into the following areas: 1. Identification of: a) families with high prevalence of dilated cardiomyopathy (DCM) (Project 1), and b) families with high prevalence of arrhythmogenic right ventricular dysplasia (ARVD)(Project 3.) 2. Characterization of subjects participating in projects 1, and 3 as to: a) basic demographics and symptomatic status b) detailed family pedigree c) presence or absence of echocardiographic criteria for DCM with 3 categories established: normal or unaffected, affected and indeterminate d) presence or absence of diagnostic criteria for ARVD with 3 categories established: normal or unaffected, affected and indeterminate. e) presence (or absence) of associated clinical conditions that reduce the odds of having DCM or ARVD 3. Coordinate patient recruitment, hemodynamic and functional evaluation, and procurement of myocardial biopsies for project 5. 4. Obtain and distribute human myocardial tissues for projects 3 and 5, including endomyocardial biopsy samples and explanted hearts.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL054313-08
Application #
6564977
Study Section
Project Start
2002-02-01
Project End
2003-01-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
$184,963
Indirect Cost

  Institution

Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Nassif, Michael E; LaRue, Shane J; Raymer, David S et al. (2016) Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circ Heart Fail 9:
Adamo, Luigi; Nassif, Michael; Tibrewala, Anjan et al. (2015) The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients. JACC Heart Fail 3:283-90
Nassif, Michael E; Patel, Jayendrakumar S; Shuster, Jerrica E et al. (2015) Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail 3:146-53
Mann, Douglas L; Mochly-Rosen, Daria (2013) Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12:327-8
Lombardi, Raffaella; Rodriguez, Gabriela; Chen, Suet Nee et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119:1398-407
Lombardi, Raffaella; Bell, Achim; Senthil, Vinitha et al. (2008) Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. Cardiovasc Res 79:109-17
Mann, Douglas L; Bozkurt, Biykem; Torre-Amione, Guillermo et al. (2008) Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 1:142-5
Daw, E W; Lu, Y; Marian, A J et al. (2008) Identifying modifier loci in existing genome scan data. Ann Hum Genet 72:670-5
Marian, Ali J (2008) Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol 23:199-205
Daw, E Warwick; Chen, Suet Nee; Czernuszewicz, Grazyna et al. (2007) Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. Hum Mol Genet 16:2463-71

Showing the most recent 10 out of 69 publications